市場調查報告書
商品編碼
922067

全球經導管肺動脈瓣市場:成長,趨勢,及預測

Transcatheter Pulmonary Valve Market - Growth, Trends, and Forecasts (2020 - 2025)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球經導管肺動脈瓣市場的相關調查,市場機會和趨勢,成長及阻礙因素,各技術、用途、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 先天性心臟病的負擔增加
    • 經導管肺動脈瓣療法的認識高漲
  • 市場阻礙因素
    • 替代技術的可用性
    • 嚴格法規
  • 波特的五力分析

第5章 市場區隔

  • 各技術
    • 球囊擴張型經導管瓣膜
    • 自我擴張型經導管瓣膜
  • 各用途
    • 肺動脈瓣狹窄
    • 肺動脈瓣逆流
    • 肺動脈封閉
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 其他地區

第6章 競爭情形

  • 企業簡介
    • Boston Scientific Corporation
    • Braile Biomedica
    • CryoLife, Inc.
    • Edwards Lifesciences Corporation
    • JenaValve Technology, Inc
    • LivaNova PLC
    • Medtronic PLC
    • Venus Medtech

第7章 市場機會及今後趨勢

目錄
Product Code: 67659

Transcatheter Pulmonary Valve therapy usually restores pulmonary valve function while delaying open-heart surgery as long as possible. It has become the treatment of choice in most congenital heart disease patients. The growing burden of congenital heart disease and increasing awareness of transcatheter pulmonary valve therapy is the main factor that is boosting the growth of the transcatheter pulmonary valve market. Additionally, the rising geriatric population will surge the demand for these valves in the future years. According to the World Health Organization (WHO), between 2015 and 2050, the proportion of the world's population over 60 years will nearly double from 12% to 22%. The growing geriatrics population with heart valve disorders is expected to rise. However, the availability of alternative technologies and stringent regulations is expected to impede the growth of the global market in the forecast period.

Key Market Trends

Balloon-Expanded Transcatheter Valve is Expected to Show Better Growth in the Forecast Period

Based on technology, the market is segmented into Balloon-Expanded Transcatheter Valve and Self-Expanded Transcatheter Valve. Balloon-Expanded Transcatheter Valve segment is expected to show better growth in the forecast period, owing to their high adoption rate and rising development of new products. The high growth is attributed to the growing interest of manufacturers in balloon expanded technology and rising awareness among the population. Transcatheter valves offer a shorter and easier procedure and faster recovery. They also offer a nonsurgical alternative to patients who are not fit to undergo surgery. The high accuracy and precision of the results using this technology are also expected to support transcatheter pulmonary valve market growth.

North America is Expected to Lead the Transcatheter Pulmonary Valve Market

North America is expected to lead the transcatheter pulmonary valve market, owing to the presence of the highly developed healthcare sector, along with the increasing prevalence of disorders such as pulmonary stenosis and regurgitation. Moreover, Congenital Heart Disease (CHD) is a leading cause of birth defect-associated infant illness and death. According to the Centers for Disease Control and Prevention (CDC), CHD affects nearly 1% or about 40,000 births per year in the United States. Other factors such as increased awareness, growing demand for innovative heart valves and rising healthcare expenditure is expected to drive the market in the forecast period.

Competitive Landscape

The leading players in the global market for the transcatheter pulmonary valve are - Boston Scientific Corporation, Braile Biomedica, CryoLife, Inc., Edwards Lifesciences Corporation, JenaValve Technology, Inc, LivaNova PLC, Medtronic PLC and Venus Medtech.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Congenital Heart Disease
    • 4.2.2 Increasing Awareness of Transcatheter Pulmonary Valve Therapy
  • 4.3 Market Restraints
    • 4.3.1 Availability of Alternative Technologies
    • 4.3.2 Stringent Regulations
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Technology
    • 5.1.1 Balloon-Expanded Transcatheter Valve
    • 5.1.2 Self-Expanded Transcatheter Valve
  • 5.2 By Application
    • 5.2.1 Pulmonary Stenosis
    • 5.2.2 Pulmonary Regurgitation
    • 5.2.3 Pulmonary Atresia
    • 5.2.4 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Rest of the World

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Boston Scientific Corporation
    • 6.1.2 Braile Biomedica
    • 6.1.3 CryoLife, Inc.
    • 6.1.4 Edwards Lifesciences Corporation
    • 6.1.5 JenaValve Technology, Inc
    • 6.1.6 LivaNova PLC
    • 6.1.7 Medtronic PLC
    • 6.1.8 Venus Medtech

7 MARKET OPPORTUNITIES AND FUTURE TRENDS